MedTrace Logo

Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects

NCT03901781 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-08-23

No results posted yet for this study

Summary

The primary objective of this trial is to assess the safety of ST266 given by non-invasive intranasal trans-cribriform delivery to glaucoma suspect subjects with ocular hypertension, optic nerve cupping, or family history of glaucoma.

Conditions

Interventions

COMBINATION_PRODUCT

ST266 via Intranasal Delivery

ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.

Sponsors & Collaborators

  • Noveome Biotherapeutics, formerly Stemnion

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-23
Primary Completion
2022-05-20
Completion
2022-05-20
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03901781 on ClinicalTrials.gov